Mutated RAS: Targeting the "Untargetable" with T Cells

被引：30

作者：

Chatani, Praveen D. ^{[1
]}

Yang, James C. ^{[1
]}

机构：

[1] NCI, Surg Branch, NIH, Bldg 10, Bethesda, MD 20892 USA

来源：

CLINICAL CANCER RESEARCH | 2020年 / 26卷 / 03期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; METASTATIC MELANOMA; K-RAS; CANCER-IMMUNOTHERAPY; PEPTIDE VACCINATION; COLORECTAL-CANCER; ADOPTIVE TRANSFER; CTLA-4; BLOCKADE; MUTANT KRAS; CODON; 12;

D O I：

10.1158/1078-0432.CCR-19-2138

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The RAS family of proteins is at the apex of several pathways implicated in a multitude of epithelial cancers but has remained stubbornly resistant to the wave of targeted small molecules and antibodies that have revolutionized clinical oncology. KRAS, the most commonly mutated of the isoforms, represents an attractive target for treatment, given its ubiquity, central role as a driver mutation, and association with poor prognosis. This review is a comprehensive summary of the existing approaches to targeting KRAS spanning small-molecule inhibitors, cancer vaccines, and with a focus on trials in adoptive cell therapy. Here we explain how the limitations of existing drugs and nonspecific immune-based therapies are circumvented with techniques in modern immunotherapy. The successes outlined represent the most promising path to finally targeting the prototypical "undruggable" RAS oncogene family.

引用

页码：537 / 544

页数：8

共 67 条

[1] Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations [J].

Abrams, SI ;

Khleif, SN ;

Bergmann-Leitner, ES ;

Kantor, JA ;

Chung, Y ;

Hamilton, JM ;

Schlom, J .

CELLULAR IMMUNOLOGY, 1997, 182 (02) :137-151

[2] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[3] Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[4] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[5] Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Itzhaki, Orit ;

Treves, Avraham J. ;

Zippel, Douglas B. ;

Levy, Daphna ;

Kubi, Adva ;

Shoshani, Noa ;

Zikich, Dragoslav ;

Ohayon, Yaara ;

Ohayon, Daniel ;

Shalmon, Bruria ;

Markel, Gal ;

Yerushalmi, Ronit ;

Apter, Sara ;

Ben-Nun, Alon ;

Ben-Ami, Eytan ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

CLINICAL CANCER RESEARCH, 2013, 19 (17) :4792-4800

[6] KRAS: feeding pancreatic cancer proliferation [J].

Bryant, Kirsten L. ;

Mancias, Joseph D. ;

Kimmelman, Alec C. ;

Der, Channing J. .

TRENDS IN BIOCHEMICAL SCIENCES, 2014, 39 (02) :91-100

[7] Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients [J].

Cafri, Gal ;

Yossef, Rami ;

Pasetto, Anna ;

Deniger, Drew C. ;

Lu, Yong-Chen ;

Parkhurst, Maria ;

Gartner, Jared J. ;

Jia, Li ;

Ray, Satyajit ;

Ngo, Lien T. ;

Jafferji, Mohammad ;

Sachs, Abraham ;

Prickett, Todd ;

Robbins, Paul F. ;

Rosenberg, Steven A. .

NATURE COMMUNICATIONS, 2019, 10 (1)

[8]

Coeshott C, 2014, P AACR SPEC C RAS ON

[9] Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses [J].

Colli, Leandro M. ;

Machiela, Mitchell J. ;

Myers, Timothy A. ;

Jessop, Lea ;

Yu, Kai ;

Chanock, Stephen J. .

CANCER RESEARCH, 2016, 76 (13) :3767-3772

[10] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

← 1 2 3 4 5 6 7 →